Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Preclinical Models.

ABSTRACT:

Background

Aggressive non-Hodgkin lymphoma (aNHL) often relapses after first-line treatment. Clinical data supports the safety and efficacy of the combination of mosunetuzumab, a CD20×CD3 bispecific antibody, and polatuzumab vedotin, an anti-CD79b antibody drug conjugate (Mosun-Pola) in relapsed/refractory aNHL. This study investigated the molecular mechanism behind the combination effect of Mosun-Pola in human diffuse large B-cell lymphoma (DLBCL) cell lines.

Methods

The in vitro Mosun-Pola efficacy in DLBCL cells (SU-DHL-8 and HT) was evaluated by T cell-dependent cellular cytotoxicity (TDCC) assay. CD20-stable-knockdown SU-DHL-8 cells were established using lentiviral short hairpin RNA. Surface and T-cell activation marker proteins expression were determined by flow cytom

SUBMITTER: Kawasaki N 

PROVIDER: S-EPMC12551598 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature